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Abstract
Background: We conducted a retrospective study in our hospital in which we compared D1 with D3 through D2
lymphadenectomy for gastric cancer in terms of morbidity, postoperative mortality, long-term survival after surgery.
Methods: 567 patients who were performed curative intent between 1980 and 2003 were enrolled. 187 in the D1
group, 189 in the D2 group and 191 in the D3 group. Every procedure was verified by pathological analyses. The
primary endpoints were 5-year overall survival.
Results: Median follow-up periods were 36 months and 60 months for D1 group and D3 group. Overall 5-year
survival rate was significantly higher in patients underwent D3 surgery than in those performed D1 surgery (37.4%
vs 48.7%; log-rank, p = 0.027). For the cases followed up to 120 months, the 10-year overall survival rate was 29%
(95% CI, 22.1% to 35.9%) for the D1 group and 33.7% (95% CI, 26.6% to 40.8%) for the D3 group (log-rank, p =
0.005).
Conclusions: D1 surgery should be operated only for patients with Borrmann I disease. As D3 gastrectomy is
associated with low mortality and adequate survival times when performed in selected institutions that have had
sufficient experience with the operation and with postoperative management, we recommend D3
lymphadenectomy for patients with curable gastric cancer.
Background
Gastric cancer is still the most common cause of cancer
related deaths worldwide, and a major clinical problem
needing to be resolved because of the poor prognosis
and the leak of treatment methods. Nowadays, surgical
management is the major treatment method for gastric
cancer. However, the efficacy of various extent of nodal
dissection is still under debate. It was reported that
improved prognosis was got in patients with gastric can-
cer who underwent D3 lymphadenectomy (first edition
of Japanese classification of gastric cancer[1-3]. Further-
more, there were some randomised multi-institutional
trials showing no survival benefits, but high morbidity
and mortality, after D3 gastric dissection compared with
D1 dissection[4,5]. To be mentioned, there were many
participating surgeons with little experience in D3 sur-
gery in these trials, hence, it’s difficult to control the
quality[4,5].
The more extended the surgery, the greater the risk of
operation related morbidity and mortality is, as reported
previously that nodal dissection increased morbidity[6].
It was reported that the postoperative mortality rate for
gastrectomy surgery oftene x c e e d s5 %i nW e s t ,e v e n
gets close to 16% in some articles,[7-9] only some Japa-
nese studies reported a lower than 2%[10]. Besides the
operation related morbidity, there was also a report
showing that lymph node dissection did not adversely
influence QOL,[11] and the operation related morbidity
did not influence survival[12,13]. * Correspondence: luping2999@yahoo.com.cn
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reported the long-term survival data for these two surgi-
cal groups of D1 and D3 taking D2 group as reference.
Finally, we demonstrated that D3 surgery has overall
survival benefit without significant operative complica-
tions and mortality.
Methods
Patients
We selected 567 patients who were histologically con-
firmed gastric cancer and underwent a radical operation
at the First Affiliated Hospital of the China Medical
University between 1980 and 2005. All of them, 187
were performed D1 dissection (D1 group), 189 received
D2 surgery (D2 group) and 191 were treated with D3
dissection (D3 group). The inclusion criteria were as fol-
lows: 1), histologically proven, potentially curablengastric
adenocarcinoma, and had physical fitness suitable for
elective operation of either type of lymphadenectomy;
2), diagnosed based on the 5th UICC TNM classification
system; 3), curative D1, D2 or D3 operations were per-
formed; 4), a complete medical record was available; 5),
patients of every period of diagnosis and every surgeon
are roughly equal; and 6), never received neoadjunctive
therapies and any kind of adjunctive therapy. Exclusion
criteria were as follows: 1), older than 75 years; 2), pre-
vious or concomitant other cancer; 3), previous or con-
comitant gastrectomy for benign disease; 4), previous
chemotherapy or radiotherapy; 5), clinical evidence of
early gastric cancer on laparotomy; 6), oesophageal
involvement; 7), macroscopically enlarged lymph nodes
around the hepatoduodenal ligament or para-aortic
regions; and 8), distant metastatic disease.
All patients were followed up by posting letters or tel-
ephone interviews. The last follow-up was December,
2008. Clinical findings, surgical findings, pathological
findings and every follow-up were collected and
recorded in the database. All the subjects gave written
informed consent to study protocol, which was
approved by the Ethics Committee of China Medical
University.
Surgical procedures and classifications of gastric cancer
Surgical procedures and pathological assessment refered
to the Japanese classification of gastric cancer[1]. All
patients in the study underwent standard total or distal
subtotal gastrectomy, depending on the location and
macroscopic appearance of the primary tumor. The defi-
nition of lymphadenectomy was based on the Japanese
Classification of Gastric Carcinoma[5]. D1–dissection of
all the group 1 nodes; D2–dissection of all the group 1
and group 2 nodes; D3–dissection of all the group 1,
group 2 and group 3 nodes. Group 1 consists of the
perigastric lymph nodes, and group 2 consists of the
lymph nodes along the left gastric artery, the common
hepatic artery, and the splenic artery and around the
celiac axis. However, when the tumor is located in the
lower third stomach, the lymph nodes along the splenic
artery are classified as group 3. Group 3 also consists of
lymph nodes in the hepatoduodenal ligament at the pos-
terior aspect of the head of the pancreas and at the root
of the mesentery.
Surgeons routinely removed lymph nodes from the
excised specimens as more as possible after operation,
based on the Japanese Classification of Gastric Carci-
noma and their experience. The specimens and retrieved
lymph nodes were stained with hematoxylin and eosin
and pathologically examined in the Gastric Laboratory
of the First Affiliated Hospital of the China Medical
University.
Endpoints and follow-up
The primary endpoints were 5-year overall survival.
Overall survival was calculated from the day of surgery
until death or the last follow-up contact. Data for a
patient were censored at last follow-up when they were
alive. Follow-up assessments were done every 6 months
for the first 5 years after surgery, and then every 12
months until death.
Statistical analyses
Data from all eligible patients were analyzed for overall
survival. Survival curves were estimated by the Kaplan-
Meier method and treatment comparisons were made
by the log-rank test.
Potential prognostic factors were entered into a Cox’s
regression model including age, sex, tumor size, site of
tumour in stomach, gross appearance, tumour stage,
clinical node status, nodal stage, joint organ removal,
gastrectomy, blood transfusion and blood loss. In multi-
variate analysis, the prognostic factor detected in uni-
variate analysis and treatment group were as covariates
included in the Cox regression model.
Two-sided P values were calculated for all tests and
are reported here. P values less than 0.05 were consid-
ered to indicate statistical significance. Analyses were
performed with the use of SPSS software, version 16.0.
Results
D1 group was with median age of 55 years old, D2
group was with median age of 55 years old and D3
group was with median age of 54 (table 1). All patients
were followed up for at least 5 years (until December
19, 2008).
The characteristics of the three groups, which were
showed in table 1, were well balanced. 125 patients had
early cancer (confined to submucosa or mucosa). 536
patients had curative resection; 31 patients had palliative
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Characteristics D1 surgery (n = 187) D2 surgery (n = 189) D3 surgery (n = 191) p Value
Age (years) 0.899
Median 55 55 54
Sex(%) 0.758
Men 136(73) 137(73) 133(70)
Women 51(27) 52(27) 58(30)
Number of lymph nodes removed 0.189
Mean 21 23 26
Number of involved lymph nodes 0.232
Mean 3 4 6
Tumor size(%) 0.323
≤5 cm 125(67) 121(64) 113(59)
5-7 cm 32(17) 40(21) 50(26)
>7 cm 30(16) 28(15) 28(15)
Site of tumour(%) 0.984
Upper stomach 44(24) 39(21) 42(22)
Middle stomach 43(23) 50(27) 45(24)
Lower stomach 88(47) 87(46) 90(47)
Whole stomach 12(6) 13(6) 14(7)
Pathological tumour stage(%) 0.979
T1 41(22) 40(21) 44(23)
T2 44(24) 45(24) 42(22)
T3 89(48) 87(46) 92(48)
T4 13(6) 17(9) 13(7)
Clinical node status(%) 0.729
Positive 182(97) 186(98) 186(97)
Negative 5(3) 3(2) 5(3)
Pathological nodal stage(%)*
N0 69(37) 60(32) 69(36) 0.500
N1 75(40) 93(49) 81(42)
N2 30(16) 26(14) 24(13)
N3 13(7) 10(5) 17(9)
Gross type(%) 0.998
Borrmann I 58(31) 56(30) 54(28)
Borrmann II 41(22) 44(23) 43(23)
Borrmann III 73(39) 74(39) 77(40)
Borrmann IV 15(8) 15(8) 17(9)
Histological type(%) 0.867
Differentiated 99(53) 88(47) 82(43)
Undifferentiated 88(47) 101(53) 109(57)
Curative resection(%) 174(93) 181(96) 181(95) 0.503
Type of gastrectomy(%) 0.440
Total 22(12) 21(11) 29(15)
Subtotal 165(88) 168(89) 162(85)
Combined organ resection 0.283
Pancreas or spleen 7(4) 16(9) 14(7)
Liver or gall 11(6) 8(4) 9(5)
Transverse colon 9(5) 17(9) 11(6)
Blood transfusion(%) 100(54) 104(55) 111(58) 0.652
*N1 = 1-6 involved nodes; N2 = 7-15 involved nodes; N3, >15 involved nodes.
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Page 3 of 10resection. 22 (12%) patients in D1 group was performed
total gastrectomy, 21 patients assigned to D2 group
(11%) and in 29 patients assigned to D3 surgery (15%).
The incidence rates of the four major surgery-related
complications in the D1 group, D2 group and D3 group
were 2% (4/187), 2% (4/189) and 2% (3/191), respec-
tively, for anastomotic leakage; 4% (8/187), 4% (7/189)
and 5% (9/191) for pancreatic fistula; 4% (8/187), 5%
(10/189) and 5% (10/191) for abdominal abscess, and 4%
(7/187), 2% (3/189) and 1% (2/191) for pneumonia.
None of these differences were statistically significant
(all P > 0.05). The hospital death rate was 2% (three
deaths in D1 group, one death in D2 group and six
deaths in D3 group).
After median follow-up periods of 36 months, 36
months and 60 months for D1 group, D2 group and D3
group respectively, 150 patients in D1 group, 157
patients in D2 group and 137 in D3 group died. Neither
the skill of an individual surgeon nor the period of diag-
nosis affected survival (p > 0.05, log-rank test). Figure 1
a n df i g u r e2s h o wt h eo v e r a l lr a t e sf o ra l le n r o l l e d
patients. There were significant differences between D1
and D3 group (p = 0.004), and between D2 and D3
group (p = 0.002). However, there was no significant dif-
ference between D1 and D2 group. The 5-year overall
survival was 37.4% (95% CI, 30.5% to 44.3%) for the D1
group and 48.7% (95% CI, 41.6% to 55.8%) for the D3
group (log-rank p = 0.027), and for those whose follow-
up periods were up to 120 months, the 10-year overall
survival was 29% (95% CI, 22.1% to 35.9%) for the D1
group and 33.7% (95% CI, 26.6% to 40.8%) for the D3
group (log-rank p = 0.005).
The hazard ratio for death was 0.708 (95% CI, 0.560-
0.894; p = 0.004) in the D3 group (table 2, univariable
analyses). After adjustment of thirteen baseline variables
(age, sex, tumor size, tumor location, Borrmann type, T
stage, clinical node status, lymph-node stage, histological
type, joint organ removal, gastrectomy, blood transfu-
sion and blood loss) with the use of Cox regression ana-
lysis, the hazard ratio was hardly unchanged (hazard
ratio, 0.771 (95% CI, 0.599-0.992); P = 0.043) (table 2,
multivariable analyses). Expectedly, the multivariate ana-
lyses showed that >7 cm in tumor size, the upper third
tumor and the whole stomach tumor, Borrmann III
type, N3 disease, D1 and D2 dissection were signifi-
cantly associated with poor survival (table 2).
As shown in table 3 and 4, D1 group got significantly
more benefit than D2 or D3 group only for Borrmann I
and N3 disease, the hazard ratios for death in the D1
group were 0.618 (95% CI, 0.399-0.958; P = 0.031) and
0.369 (95% CI, 0.162-0.841; P = 0.018), respectively.
D3 group has significantly more benefit than D1 and
D2 surgery in the subgroups of cases with ≤5c ma n d
>7 cm tumors, the lower third tumor, Borrmann II and
III types, T3 stage, positive clinical node, N0 and N1
disease, no joint organ removal, the subtotal gastrect-
omy, blood transfusion and 200-400 ml blood loss.
There was no evidence indicating that D2 surgery has
any significant benefit for these subgroups.
Discussion
In the study, we found significant improvement in over-
all survival with D3 surgery compared to D1 surgery.
Figure 1 The overall rates for all enrolled patients. There were
significant differences between D1 and D3 group (p = 0.004), and
between D2 and D3 group (p = 0.002). However, there was no
significant difference between D1 and D2 group.
Figure 2 The 5-year overall survival for all enrolled patients.
The 5-year overall survival was 37.4% (95% CI, 30.5% to 44.3%) for
the D1 group and 48.7% (95% CI, 41.6% to 55.8%) for the D3 group
(log-rank p = 0.027).
Zhang et al. BMC Cancer 2010, 10:308
http://www.biomedcentral.com/1471-2407/10/308
Page 4 of 10Table 2 HR for death in intention-to-treat population (n = 567)–univariable and multivariable analyses
Univariable analyses Multivariable analyses
HR (95% CI) p* HR (95% CI) p†
Age (years) 0.033 0.335
≤55 1 (Ref) 1 (Ref)
>55 1.231(1.017-1.490) 0.033 1.224(0.982-1.524) 0.335
Sex 0.816 0.960
Women 1 (Ref) 1 (Ref)
Men 1.025(0.833-1.261) 0.816 0.943(0.748-1.188) 0.960
Tumor size 0.000 0.111
≤5 cm 1 (Ref) 1 (Ref)
5-7 cm 1.527(1.217-1.917) 0.000 1.266(0.991-1.617) 0.059
>7 cm 1.728(1.338-2.233) 0.000 1.397(1.005-1.943) 0.047
Tumour site 0.101 0.005
Upper stomach 1 (Ref) 1 (Ref)
Middle stomach 0.624(0.477-0.816) 0.001 0.585(0.436-0.786) 0.000
Lower stomach 0.626(0.495-0.792) 0.000 0.634(0.482-0.833) 0.001
Whole stomach 1.303(0.889-1.910) 0.174 0.698(0.422-1.154) 0.161
Gross appearance 0.000 0.000
Borrmann types I 1 (Ref) 1 (Ref)
Borrmann types II 1.080(0.824-1.416) 0.576 0.979(0.740-1.294) 0.879
Borrmann types III 1.723(1.364-2.175) 0.000 1.601(1.253-2.046) 0.000
Borrmann types IV 2.141(1.507-3.044) 0.000 1.282(0.841-1.952) 0.248
Tumour stage 0.000 0.651
T1 1 (Ref) 1 (Ref)
T2 0.855(0.638-1.146) 0.295 0.799(0.590-1.082) 0.146
T3 1.262(0.956-1.615) 0.064 0.917(0.698-1.205) 0.535
T4 1.867(1.284-2.716) 0.001 1.005(0.657-1.537) 0.983
Clinical node status 0.372 0.438
Negative 1 (Ref) 1 (Ref)
Positive 1.376(0.683-2.770) 0.372 1.652(0.794-3.436) 0.438
Lymph-node stage 0.000 0.000
N0 1 (Ref) 1 (Ref)
N1 1.342(1.082-1.666) 0.008 1.119(0.863-1.450) 0.397
N2 1.480(1.099-1.994) 0.010 1.238(0.889-1.725) 0.206
N3 3.603(2.497-5.199) 0.000 2.653(1.684-4.179) 0.000
Histological type(%) 0.221 0.556
Differentiated 1 (Ref) 1 (Ref)
Undifferentiated 1.177(0.591-1.529) 0.221 0.897(0.624-1.289) 0.556
Joint organ removal 0.000 0.000
None 1 (Ref) 1 (Ref)
Pancreas or spleen 1.964(1.374-2.808) 0.000 1.364(0.902-2.062) 0.141
Liver or gall 1.380(0.896-2.125) 0.144 1.291(0.823-2.023) 0.266
Transverse colon 1.882(1.321-2.681) 0.000 1.446(0.984-2.125) 0.060
Gastrectomy 0.000 0.001
Total 1 (Ref) 1 (Ref)
Subtotal 0.549(0.422-0.714) 0.000 0.833(0.563-1.233) 0.001
Blood transfusion 0.356 0.580
No 1 (Ref) 1 (Ref)
Yes 1.094(0.904-1.324) 0.356 1.003(0.815-1.234) 0.580
Blood loss 0.789 0.199
≤200 ml 1 (Ref) 1 (Ref)
200-400 ml 0.901(0.723-1.122) 0.350 0.900(0.715-1.134) 0.373
>400 ml 1.049(0.816-1.347) 0.710 0.736(0.552-0.980) 0.036
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Page 5 of 10Table 3 Tests for Heterogeneity of Treatment Effect According to the Clinicopathological Characteristics of the D1 and
D3 Patients.
Subgroup D1 surgery D3 surgery HR (95% CI) P
No. of deaths/no. of patients
Total 150/187 137/191 1.407(1.113-1.779)
Age (years)
≤55 49/66 70/107 1.384(0.955-2.004) 0.086
>55 101/121 67/84 1.242(0.911-1.693) 0.170
Sex
Women 41/51 44/58 1.248(0.815-1.912) 0.309
Men 109/136 93/133 1.463(1.103-1.939) 0.008*
Tumor size
≤5 91/125 74/113 1.401(1.028-1.910) 0.033*
5-7 30/32 42/50 1.412(0.875-2.279) 0.158
>7 29/30 21/28 1.917(1.075-3.419) 0.027*
Tumour site
Upper stomach 40/44 37/42 1.116(0.707-1.762) 0.638
Middle stomach 35/43 29/45 1.641(0.984-2.735) 0.058
Lower stomach 64/88 59/90 1.482(1.038-2.117) 0.030*
Whole stomach 11/12 12/14 1.574(0.685-3.618) 0.286
Gross appearance
Borrmann types I 37/58 35/54 1.100(0.688-1.759) 0.691
Borrmann types II 33/41 32/43 1.781(1.069-2.967) 0.027*
Borrmann types III 66/73 56/77 1.685(1.175-2.416) 0.005*
Borrmann types IV 14/15 14/17 1.708(0.810-3.600) 0.160
Tumour stage
T1 29/41 24/44 1.723(0.992-2.992) 0.054
T2 30/44 29/42 1.282(0.754-2.178) 0.359
T3 79/89 71/92 1.431(1.037-1.977) 0.029*
T4 12/13 13/13 1.071(0.485-2.365) 0.866
Clinical node status
Negative 4/5 2/5 3.070(0.533-17.703) 0.209
Positive 146/182 135/186 1.382(1.091-1.752) 0.007*
Lymph-node stage
N0 50/69 42/69 1.781(1.168-2.718) 0.007*
N1 64/75 60/81 1.504(1.055-2.145) 0.024*
N2 24/30 19/24 1.116(0.609-2.044) 0.723
N3 12/13 16/17 0.369(0.162-0.841)† 0.018*
Histological type
Differentiated 62/99 49/82 1.143(0.761-1.563) 0.231
Undifferentiated 62/99 50/88 49/82 56/109 1.047(0.773-1.732) 0.334
Table 2: HR for death in intention-to-treat population (n = 567)–univariable and multivariable analyses (Continued)
Lymph node dissection 0.004 0.045
D1 1 (Ref) 1 (Ref)
D2 1.019(0.815-1.275) 0.869 1.024(0.801-1.308) 0.851
D3 0.708(0.560-0.894) 0.004 0.771(0.599-0.992) 0.043
Ref = reference category.
*Derived from tests of HR for prognostic factors in univariate model adjusted for treatment group in Cox proportional-hazards model.
†Cox-regression analysis, controlling for prognostic factors listed in table.
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Page 6 of 10Table 3: Tests for Heterogeneity of Treatment Effect According to the Clinicopathological Characteristics of the D1
and D3 Patients. (Continued)
Joint organ removal
None 127/160 104/157 1.703(1.309-2.217) 0.000*
Pancreas or spleen 6/7 14/14 0.754(0.285-1.996) 0.569
Liver or gall 9/11 9/9 0.532(0.200-1.415) 0.206
Transverse colon 8/9 10/11 0.403(0.144-1.133) 0.085
Gastrectomy
Total 20/22 26/29 1.259(0.697-2.274) 0.444
Subtotal 130/165 111/162 1.495(1.156-1.932) 0.002*
Blood transfusion
No 63/87 52/80 1.316(0.909-1.906) 0.146
Yes 87/100 85/111 1.485(1.097-2.011) 0.011*
Blood loss
≤200 41/54 41/49 0.858(0.555-1.328) 0.493
200-400 68/88 56/83 1.623(1.130-2.332) 0.009*
>400 41/45 40/59 2.060(1.327-3.198) 0.001*
The P values are for hazard ratios for death in the group assigned to D1 lymphadenectomy and the group assigned to D3 lymphadenectomy, with 95%
confidence intervals.
The surgery is better for D1 lymphadenectomy when the HR is <1; and is better for D3 lymphadenectomy when the HR is >1.
†Significantly better for D1 lymphadenectomy.
*Considered significant.
Table 4 Tests for Heterogeneity of Treatment Effect According to the Clinicopathological Characteristics of the D1 and
D2 Patients.
Subgroup D1 surgery D2 surgery HR (95% CI) p
No. of deaths/no. of patients
Total 150/187 157/189 0.982(0.785-1.229)
Age (years)
≤55 49/66 88/107 0.877(0.618-1.244) 0.462
>55 101/121 69/82 1.016(0.748-1.380) 0.919
Sex
Women 41/51 40/52 1.308(0.843-2.029) 0.231
Men 109/136 117/137 0.878(0.676-1.140) 0.329
Tumor size
≤5 91/125 97/121 0.921(0.692-1.227) 0.575
5-7 30/32 34/40 1.178(0.714-1.941) 0.522
>7 29/30 26/28 1.143(0.672-1.945) 0.622
Tumour site
Upper stomach 40/44 32/39 1.205(0.752-1.930) 0.438
Middle stomach 35/43 41/50 1.086(0.691-1.706) 0.721
Lower stomach 64/88 72/87 0.806(0.575-1.130) 0.212
Whole stomach 11/12 12/13 1.062(0.464-2.429) 0.887
Gross appearance
Borrmann types I 37/58 45/55 0.618(0.399-0.958) † 0.031*
Borrmann types II 33/41 31/44 1.189(0.727-1.945) 0.490
Borrmann types III 66/73 66/74 1.327(0.938-1.878) 0.110
Borrmann types IV 14/15 15/16 1.105(0.528-2.312) 0.791
Tumour stage
T1 29/41 35/40 0.755(0.458-1.243) 0.269
T2 30/44 32/45 1.093(0.661-1.808) 0.729
T3 79/89 75/87 1.073(0.782-1.473) 0.662
T4 12/13 15/17 0.854(0.383-1.906) 0.700
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Page 7 of 10Furthermore, no significant difference was found in the
incident rates of major surgery-related complications
between the two groups, which was similar to the
results in the trials done in Hong Kong,[14] the UK,[5]
and Dutch[15].
We conducted a post hoc subgroup analysis including
thirteen variables.To be interest, the results indicated
that D1 surgery got significantly more benefit than D3
surgery for N3 disease, while D3 surgery has signifi-
cantly more benefit than D1 surgery in the subgroups of
N0 and N1 disease. Since this result was from a post
hoc subgroup, it might be a false positive owing to mul-
tiple testing,[16] the possible survival benefit of D3 lym-
phadenectomy in node-negative patients will need to be
clarified in further studies.
In a review article, Sun Hu Yang et alreported that
there was no difference in the 3- or 5-year survival
between D1 and D2[17]. In the study, the 5-year overall
survival was 37.4% for D1 group and 48.7% for D3
group, and the period of diagnosis didn’t affect survival
(p = 0.084, log-rank test)[18]. It can be seen that long-
term survival is lower, when comparing our results with
historical report, in which the observed 5-year survival
rates were 53.6% and 59.5%, respectively[13]. This result
indicated that the time of diagnosis of malignant
tumours as well as gastric cancer is much later in China
than in other countries, especially western countries.
In this study, we found that more than 60% of both
the D1 and D3 patients had lymph node metastases
which was higher than the report of Bunt et al[19]. In
the D3 group, which includes lymph node dissection of
the N1, N2 and N3 level, there were 42% being classified
as N1, 13% as N2, and 9% as N3. The extended surgery
is considered to be related to the risk of operative mor-
bidity and mortality[6]. The mortality for gastrectomy in
Western countries was usually5% and even approaches
16% in some trials[7-9].
Robert C G et al reported that the overall 5-year sur-
vival rate for the 286 patients undergoing gastrectomy
with additional organ resection was 32%, which was
Table 4: Tests for Heterogeneity of Treatment Effect According to the Clinicopathological Characteristics of the D1
and D2 Patients. (Continued)
Clinical node status
Negative 4/5 2/3 2.654(0.458-15.362) 0.276
Positive 146/182 155/186 0.965(0.770-1.210) 0.759
Lymph-node stage
N0 50/69 46/60 1.004(0.672-1.500) 0.984
N1 64/75 80/93 1.040(0.748-1.446) 0.814
N2 24/30 21/26 0.820(0.455-1.477) 0.508
N3 12/13 10/10 0.376(0.153-0.922)† 0.033*
Histological type
Differentiated 62/99 55/88 1.033(0.921-1.783) 0.136
Undifferentiated 50/88 56/101 1.157(0.833-1.947) 0.390
Joint organ removal
None 127/160 124/148 0.960(0.749-1.229) 0.745
Pancreas or spleen 6/7 13/16 1.340(0.502-3.575) 0.559
Liver or gall 9/11 4/8 2.959(0.796-10.992) 0.105
Transverse colon 8/9 16/17 0.659(0.277-1.566) 0.345
Gastrectomy
Total 20/22 20/21 1.089(0.583-2.036) 0.788
Subtotal 130/165 137/168 0.970(0.763-1.233) 0.802
Blood transfusion
No 63/87 70/85 0.900(0.640-1.265) 0.543
Yes 87/100 87/104 1.056(0.785-1.422) 0.718
Blood loss
≤200 41/54 57/70 0.920(0.616-1.375) 0.685
200-400 68/88 67/73 0.703(0.501-0.986) † 0.041*
>400 41/45 33/46 1.870(1.175-2.977) 0.008*
The P values are for hazard ratios for death in the group assigned to D1 lymphadenectomy and the group assigned to D2 lymphadenectomy, with 95%
confidence intervals.
The surgery is better for D1 lymphadenectomy when the HR is <1; and is better for D2 lymphadenectomy when the HR is >1.
†Significantly better for D1 lymphadenectomy.
*Considered significant.
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Besides the surgery extent, the participating surgeons’
operative skill and experience, and the workload cases
are also important factors for survival rates[21,22].
There are many studies having reported a relationship
between the number of cases treated in a hospital and
the outcomes of cancer treatment[22-27]. Moreover, the
uniformity of treatment is also important. Our study
was carried out in a hospital that performs a high
volume of nodal dissections for gastric cancer with low
morbidity and mortality rates. In our study, all partici-
pating surgeons were of the same department, which
minimizes the variation in individual operating skill and
management, and did an equal number of D1 and D3
resections during the trial, which balances the compari-
sons between the two groups without bias to individual
surgeons’ skill. Therefore, the experience as a result of
caseload, surgical skill, and the case selection are very
important[5,28,29].
Conclusions
As D3 gastrectomy is associated with low mortality and
adequate survival time when performed in selected insti-
tutions that have had sufficient experience with the
operation and with post-operative management, we
recommend D3 lymphadenectomy for patients with cur-
able gastric cancer except for patients with Borrmann I
disease who are more suitable for D1 surgery.
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